Investors in healthcare and biotech sectors should keep an eye on several prominent companies making strides in innovation, clinical trials, and global expansion. Modular Medical (NASDAQ: MODD), Cardiol Therapeutics (NASDAQ: CRDL), DBV Technologies (NASDAQ: DBVT), and Virax Biolabs (NASDAQ: VRAX) are key players to watch in the ever-evolving medical landscape. Each company has announced significant developments in technology, trials, and product distribution, solidifying their positions in the market.
Modular Medical Secures U.S. Patent for Key Insulin System Pumping Technology
Modular Medical, Inc. (NASDAQ: MODD) has strengthened its intellectual property portfolio with the issuance of U.S. Patent No. 17/968,599, covering critical components of its MODD1 insulin delivery system. The patent protects key features of the FDA-cleared device, which is designed to provide affordable and accurate insulin pumping for adult users. “This patent enhances our strategic market value and reinforces our commitment to innovation in diabetes care,” said CEO Jeb Besser. The MODD1 insulin pump simplifies diabetes management, providing users with a cost-effective alternative to traditional pumps. Modular Medical continues to expand its patent portfolio, solidifying its position as a leader in insulin delivery technology.
Cardiol Therapeutics Advances Late-Stage Trial for Pericarditis with CardiolRx
Cardiol Therapeutics Inc. (NASDAQ: CRDL) is moving forward with its MAVERIC-2 clinical trial, aimed at evaluating CardiolRx™ for patients with recurrent pericarditis. This trial focuses on individuals discontinuing interleukin-1 blocker therapy and will be conducted at leading medical centers across the U.S. and Europe. CardiolRx™ has shown promise in reducing pain and inflammation in earlier studies, offering hope for those affected by recurrent pericarditis. Full data will be presented at the American Heart Association Scientific Sessions in November 2024, further highlighting the potential of CardiolRx™ as a treatment option that could reduce dependency on immunosuppressive therapies.
DBV Technologies Showcases Viaskin Peanut Patch at ACAAI Annual Meeting
DBV Technologies (NASDAQ: DBVT), a leader in food allergy treatments, will showcase its flagship product, the Viaskin® Peanut patch, at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting in late October 2024. The Viaskin Peanut patch is designed to desensitize peanut allergy sufferers using epicutaneous immunotherapy (EPIT™), delivering small doses of peanut antigen through the skin. The patch, currently awaiting FDA and EMA approval, is seen as a breakthrough for individuals with peanut allergies, offering a non-invasive treatment option that could dramatically reduce allergic reactions.
Virax Biolabs Expands Global Distribution of ImmuneSelect Portfolio
Virax Biolabs (NASDAQ: VRAX) continues its global expansion with the distribution of its ImmuneSelect Research Use portfolio in partnership with Europa Biosite and Cambridge Bioscience. ImmuneSelect was recently launched at the 2024 ESCMID Congress, and its focus on evaluating T-cell immunity has attracted significant interest in post-viral syndrome research, including Long COVID. While these products are intended for research purposes and not diagnostics, they are instrumental in advancing the understanding of immune response and aiding global scientific efforts.
These companies, each making groundbreaking advances in healthcare, technology, and medical research, present significant opportunities for investors and industry professionals alike. With innovative products and clinical trials underway, Modular Medical (NASDAQ: MODD), Cardiol Therapeutics (NASDAQ: CRDL), DBV Technologies (NASDAQ: DBVT), and Virax Biolabs (NASDAQ: VRAX) are at the forefront of the healthcare sector’s evolution, addressing critical medical challenges and improving patient outcomes globally. As they continue to push boundaries, investors and medical professionals should closely monitor their progress. The advancements being made by these companies are shaping the future of healthcare, offering new solutions that enhance quality of life and drive better global health outcomes.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com